However, another trial revealed that while no significant difference in PFS was observed between patients with stage III/IV melanoma unselected for BRAF mutations, five of six patients with partial response to AZD had BRAF‐mutant tumors (mostly V600E) 31. This evidence concerns the gene BRAF and melanoma.